Media Release

May 20, 2003 01:30 ET | Source: Novartis Pharma AG Novartis Pharma AG

Basel, 20 May 2003 - New data from a large pivotal US trial demonstrates ZelmacÒ* (tegaserod) was significantly more effective than placebo in providing rapid and sustained relief from chronic constipation based on a trial of more than 1,300 patients. Furthermore, Zelmac provided relief of several chronic constipation symptoms including bowel movement frequency, straining, stool consistency, abdominal discomfort or pain, bloating or distension.

Attachments

Media Release...

Company ProfileNovartis Pharma AGIndustry: PharmaceuticalsWebsite:

https://novartis.com

Press Release Actions

Recommended Reading

April 02, 2025 20:13 ET | Source: Novartis Pharma AG

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation...
Read More
March 31, 2025 01:00 ET | Source: Novartis Pharma AG

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of...
Read More